We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Calquence also maintained efficacy and a sustained safety profile at four years for previously treated patients in the company’s ASCEND trial. Read More
Bristol Myers Squibb’s blockbuster checkpoint inhibitor Opdivo (nivolumab) snagged approvals for two more indications as add-on therapy for unresectable or metastatic esophageal squamous-cell carcinoma. Read More
Under the terms of the accelerated approval, the company must conduct one or more confirmatory clinical trials to demonstrate the treatment’s benefit. Read More